Sign Up to like & get
recommendations!
1
Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.09.015
Abstract: OBJECTIVES There are limited treatment options for patients with thymic malignancies. Here we present data supporting treatment with single agent amrubicin, a third generation anthracycline and topoisomerase II inhibitor. MATERIALS AND METHODS This was a…
read more here.
Keywords:
agent;
single agent;
thymic malignancies;
amrubicin patients ... See more keywords